Apt Therapeutics, Inc.

Humanzyme Limited

Monsanto Technology LLC

Renessen LLC

Monsanto Company

Astrazeneca Ab

Rapp, William

Slater, Steven

Liang, Jihong

Jeong, Soon Seog

Weaver, Lisa M.

Chen, Ridong

Mitsky, Timothy

Soon Seog Jeong

Ridong Chen

Timothy A Mitsky

Lisa M Weaver

Steven Slater

Jihong Liang

Lisa Marie Weaver

Steven C Slater

William D Rapp

Hui Feng

The present technology relates to engineered human Fibroblast Growth Factor-2 (FGF2) proteins and methods of using the same. In particular, the methods and compositions relate to FGF2 mutants with increased thermostability compared to the wild-type protein and method for using the proteins in the culturing of embryonic stem cells.

Thermostable variants of fibroblast growth factors

This invention provides a new class of enhanced apyrases (EN-apyrases) with superior pharmacokinetic, pharmacodynamic, and pharmacochemical properties and which can be purified using simplified procedures. The invention further provides constructs for transforming a cell to produce these EN-apyrases. The EN-apyrase construct comprises sequences encoding a signal sequence, a linker, and a soluble apyrase. Also provided are preparations of apyrases and methods for producing apyrase in culture cells and purification thereof.

Therapeutic apyrase constructs, apyrase agents, and production methods

This invention provides new methods of treating subjects experiencing or at risk of bleeding due to vascular injury, especially to the microvasculature and/or platelet desensitization. Examples of injury usefully treated by apyrase agents are pathophysiological conditions, ischemia reperfusion injury, injury from pharmacologic agents such as anticoagulants, antiplatelet agents, antithrombotics, thrombolytics, and/or immunosuppressants, and injury resulting from transplantation. Apyrase agents are also useful to maintain organ function when said organs are transplanted into an allogeneic recipient.

Apyrase therapy for bleeding conditions

The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.

Recombinant production of authentic human proteins using human cell expression systems

The present invention provides for design and therapeutic use of ADPase enhanced polypeptides, pharmaceutical compositions, and methods useful for preventing and reversing platelet aggregation and recruitment for the treatment and prevention of vascular disorders in mammals.

Therapeutic use of ADPase enhanced apyrases

Design and therapeutic use of adpase enhanced apyrases

The present invention provides soluble forms of CD39L3 polypeptides and compositions, and methods useful inhibiting platelet activation and recruitment for the treatment and prevention of thrombotic disorders in mammals administered with soluble forms of CD39L3 polypeptides.

Therapeutic use of soluble CD39L3

The present invention provides transgenic plants transformed with an isolated DNA encoding a monomeric anthranilate synthase. The present invention also provides an isolated DNA encoding a monomeric anthranilate synthase from. Transformation vectors and transformed plants containing the isolated DNA and seeds derived therefrom, are also provided.

Transgenic high tryptophan plants

Growing community of inventors

Naperville, IL, United States of America

Soon Seog Jeong